Well, yes. But the side-effect profile of an MAOI is gigantic, so it seems odd to me that they chose an MAOI for a new transdermal system.
See my Post #23.
Selegiline is generally very well tolerated. Because it is metabolized to amphetamine derivatives, it is typically administered in the morning and at midday rather than in the evening to minimize the potential for insomnia. Some patients experience gastrointestinal side effects. Unusual side effects include increased liver enzymes and aggravation of peptic ulcer disease.
Could very well be that trans-dermal administration minimizes side effects and is easier on the tummy.